EHA 2018 | Current and future therapies in mantle cell lymphoma
Speaking from the 23rd Congress of the European Hematology Association (EHA) 2018, held in Stockholm, Sweden, Simon Rule, MD, of Plymouth University, Plymouth, UK, discusses the current landscape of mantle cell lymphoma (MCL) treatment. He points to BTK inhibitors as the most exciting therapy option, explaining how using them earlier on in the treatment pathway improves their efficacy and toxicity. Along with highlighting key clinical trials in the field, he explores the concept of combination therapies, suggesting that combining BTK and BCL2 inhibitors might lead to more effective treatment. Finally, Prof. Rule highlights the important areas for future research, including analyzing resistance pathways in relapsed patients and working out how to treat them.
Get great new content delivered to your inboxSign up